News

Holiday wishes

Vaccine Consultancy & FluConsult | Holiday wishes

Influenza Vaccines for the World 6-9 October 2015 at Albufeira

The conference Influenza Vaccines for the World was held on 6-9 October 2012 at Albufeira, Portugal. FluConsult was member of the Scientific Advisory Panel of conference, chaired the session on Adjuvants formulation and delivery for Influenza Vaccines and was sponsor of the conference.

Ronald Kompier is member of advisory board of the Swedish company Swecure

Swecure is a Swedish biotechnology company developing preventive treatments for allergies. The company is working to reduce the prevalence of allergies and to improve the quality of life for mankind. Swecure is based out of research in bacteriology and immunology from Sahlgrenska University Hospital with more than 15 years of experience in infant gut bacterial flora. Swecure’s technology represents the world’s first prophylactic approach to allergies. No similar product exists on the market or in the current pipeline of any big pharmaceutical company. Swecure however has identified a bacterial protein with the unique ability to activate immunological tolerance mechanisms in the first weeks of life, stopping allergies before they even develop. Swecure is a portfolio company of Serendipity Ixora, a venture capital firm specializing in research-intensive ventures. read more on Swecure >>

Holiday wishes

FluConsult | Holiday wishes

Options for the Control of Influenza VIII

5-10th of September 2013, Cape Town, South Africa

Ronald Kompier has attended the Options for the Control of Influenza VIII on September 5-10, 2013, Cape Town, South Africa.

The Disposable Solutions for Biomanufacturing Summit

19-20th of February 2013, Brussels, Belgium

Ronald Kompier has attend the Disposable Solutions for Biomanufacturing Summit on February 19 & 20, 2013, Brussels, Belgium.

Advancing BioProcessing Technology Knowledge and Applications

13-14th June 2012, Brussels, Belgium
Ronald Kompier attended the BioProcessing Technology Seminar: Advancing BioProcessing Technology Knowledge and Applications in Brussels, June 13-14th, 2012.

Influenza Vaccines for the World 9-12 October 2012 at Valencia

The conference Influenza Vaccines for the World was held on 9-12 October 2012 at Valencia, Spain. FluConsult was member of the Scientific Advisory Panel of conference, chaired the session on Adjuvants for Influenza Vaccines and was sponsor of the conference. The conference was a great succes and FluConsult is now known to all conference members.

Member of advisory board of the Swedish
company Premune

Premune stands for leading expertise in allergy prevention, with the most extensive research in infant gut flora. By early stimulation of the immune system, Premune is boosting the body’s natural tolerance mechanisms – significantly reducing the risk of developing allergies. With a new way of looking at allergies, Premune’s prophylactic treatment is preventing the allergic march before it has begun. read more on Premune >>

Member of Scientific Advisory Panel of conference "Influenza Vaccines for the World"

being held on 9-12 October 2012 at Valencia, Spain
The Influenza Vaccines for the World conference is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants/delivery/vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines/technologies and their availability/delivery/implementation worldwide.

New publication in Vaccine, oktober 2011

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial
Rebecca J. Cox, Gabriel Pedersen, Abdullah S. Madhun, Signe Svindland, Marianne Sævik, Lucy Breakwell, Katja Hoschler, Marieke Willemsen, Laura Campitelli, Jane Kristin Nøstbakken, Gerrit Jan Weverling, Jaco Klap, Kenneth C. McCullough, Maria Zambon, Ronald Kompier, Haakon Sjursen

The avian influenza H5 virus epizootic continues to cause zoonosis with human fatalities, highlighting the continued need for pandemic preparedness against this subtype. This study evaluated the tolerability and immunogenicity of a Matrix M™ adjuvanted virosomal H5N1 vaccine in a phase I clinical trial. Sixty healthy adults were vaccinated intramuscularly with two doses of influenza H5N1 (NIBRG-14) virosomal vaccine alone (30 μg haemagglutinin (HA)) or 1.5, 7.5 or 30 μg HA formulated with 50 μg Matrix M™ adjuvant. The antibody response was analysed by haemagglutination inhibition (HI), microneutralisation (MN) and single radial haemolysis (SRH) assays. The vaccine was well tolerated in all groups but injection site pain was more frequently observed in the Matrix M™ adjuvanted groups. The vaccine elicited homologous and heterologous H5N1-specific antibody responses and the Matrix M™ adjuvanted formulations met all the EU regulatory criteria. In conclusion, Matrix M™ adjuvant was well tolerated and augmented the antibody response allowing considerable dose sparing down to 1.5 μg HA.

Fourth ESWI Influenza Conference in Malta

Ronald Kompier has attended the 'The Fourth ESWI Influenza Conference in Malta on 11-14 September 2011'.

Ronald coauthor in Science

Ronald Kompier is coauthor in an article in the world's leading journal of original scientific research Science:

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. Damian C. Ekiert, Robert H. E. Friesen, Gira Bhabha, Ted Kwaks, Mandy Jongeneelen, Wenli Yu, Carla Ophorst, Freek Cox, Hans J.W.M. Korse, Boerries Brandenburg, Ronald Vogels, Just P.J. Brakenhoff, Ronald Kompier, Martin H. Koldijk, Lisette A.H.M. Cornelissen, Leo L. M. Poon, Malik Peiris, Wouter Koudstaal, Ian A. Wilson and Jaap Goudsmit.

In this new study, it is reported that by recognizing a novel conserved epitope in the hemagglutinin stem, the antibody CR8020 shows broad neutralizing activity against most influenza A group 2 viruses, including the H3N2 and H7N7 viruses, which cause severe human infection. Attempts to isolate broadly neutralizing antibodies against group 2 viruses have not been previously described. The broad neutralizing ability of the CR8020 makes it a potentially groundbreaking therapy against seasonal and pandemic flu.

Conference ’Single-Use Solutions in Bioprocess Technology’ | June 9 - 2011

Ronald Kompier has chaired the afternoon session of the conference ’Single-Use Solutions in Bioprocess Technology’; June 9, HAN BioCentre, Nijmegen, The Netherlands.

17 & 18 November 2010
Kavli Royal Society, London

Ronald Kompier has presented at a meeting on 'Accelerating Vaccine Development' at the Kavli Royal Society in London on November 17 & 18, 2010.

This meeting on 'Accelerating Vaccine Development' with input from industrialist, regulators, academics and funders. Incentivisation strategies that have and have not worked will be reviewed along with new opportunities.

Lowering the regulatory requirements for conditional approval of certain vaccines remains an attractive option, but may be discouraged by increasing public concerns about vaccine safety.

The emergence of large scale high quality vaccine manufacturers in several developing countries along with many new national regulatory authorities add new complexity but also opportunities.

Conference Hong Kong | 3-7 september

FluConsult has attended the Options for the Control of Influenza VII in Hong Kong 3- 7 september 2010.

The Options for the Control of Influenza is the largest and most comprehensive conference exclusively devoted to the study, diagnosis and treatment of influenza.

Ronald Kompier

footer fluconsult